Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: Use as a possible therapeutic approach of osteosarcoma

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Théoleyre, Sandrine ^a   Mori, K ^a   Cherrier, Bertrand ^a   Passuti, Norbert ^a   Gouin, Francois ^a   Rédini, Francoise ^a   Heymann, Dominique ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; TUMOR ANTIGEN;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BONE TUMOR; CANCER THERAPY; CELL ACTIVITY; CELL ISOLATION; CHONDROSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; EWING SARCOMA; EXTRACTION; FEMALE; GIANT CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE FUNCTION; LYMPHOCYTOTOXICITY; MALE; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PLASMACYTOMA; RAT; SAMPLING; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR CELL DESTRUCTION; ANIMAL; CD4+ T LYMPHOCYTE; CYTOLOGY; DISEASE MODEL; FLOW CYTOMETRY; IMMUNOTHERAPY; LEUKOCYTE; LYMPHOCYTE; MELANOMA; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; OSTEOLYSIS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; ANIMALS; BONE NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; LEUKOCYTES; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOLYSIS; OSTEOSARCOMA; PHENOTYPE; PROGNOSIS; RATS;

EID: 26844523588     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-123     Document Type: Article

References (48)

1. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC: Chemotherapy, en bloc resection, and prosthetic bone replacement in treatment of osteogenic sarcoma. Cancer 1976, 37:1-11.
2. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J: Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin Orthop 1991, 270:8-14.
3. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS: Treatment of non-metastatic osteosarcoma of the extremity with pre-operative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997, 15:76-84.
4. Rosenberg SA, Spiess P, Lafreniere R.: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321.
5. Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA: Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991, 83: 932-937.
6. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature, 2001, 411: 380-384.
7. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003, 26: 332-342.
8. Fabbri M, Ridolfi R, Maltino R, Ridolfi L, Riccobon A, Flamini E, De Paola F, Verdecchia GM, Amadori D: Tumor infiltrating lymphocytes and continous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma. Tumori 2000, 86: 46-52.
9. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF: Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005, 28: 258-267.
10. El Hage F, Vergnon I, Grunenwald D, Soria JC, Chouaib S,Mami-Chouaib F: Generation of diverse mutated tumor antigen-specific cytotoxic T lymphocytes in a lung cancer patient with long survival. Oncol Rep 2005, 14: 763-769.
11. Dillma, R, Schiltz P, DePriest C, Barth N, Beutel L, de Leon C, O'Connor A, Nayak S: Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm 2004, 19: 730-737.
12. Kowalczyk D, Skorupski W, Kwias Z, Nowak J: Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 1997, 80: 543-547.
13. Dierderichsen AC, Zeuthen J, Christensen PB, Kristensen T: Characterization of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur J Cancer 1999, 35: 721-726.
14. + lymphocyte infiltration and apoptosis in hepatocellular carcinoma. Eur J Surg Oncol 2004, 30: 53-57.
15. Yakirevich E, Izhak OB, Rennert G, Kovacs ZG, Resnick MB: Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol 1999, 12: 1050-1056.
16. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED: T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001, 98: 14565-14570.
17. Kobayashi M, Ito M, Sano K, Honda T, Nakayama J: Pulmonary lymphoepithelioma-like carcinoma: predominant infiltration of tumor-associated cytotoxic T lymphocytes might represent the enhanced tumor immunity. Intern Med 2004, 43: 323-326.
18. Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalifi J, Bonyhadi M, Levitsky H, Whartenby K, Borrelo I: Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005, 65: 2026-2034.
19. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G: Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 1992, 34: 241-251.
20. Zietz C, Rumpler U, Sturzl M, Lohrs U: Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack. Am J Pathol 2001, 159: 963-970.
21. + lymphocytes in canine transmissible venereal sarcomas at different stages of tumor growth. Anticancer Res 1999, 19: 1137-1142
22. Yu R, Fujio K, Tahara H, Araki Y, Yamamoto K: Clonal dynamics of tumor-infiltrating lymphocytes. Eur J Immunol 2005,35: 1754-1763.
23. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86: 1159-1166.
24. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S, Labarriere N, Jotereau F: Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002, 51: 539-546.
25. Burger UL, Chang MP, Nagoshi M, Goedegebuure PS, Eberlein TJ: Improved in vivo efficacy of TIL after restimulation with irradiated tumor cells in vitro. Ann Surg Oncol 1996, 6: 580-587.
26. Harada M, Matsuzaki G, Shinomiya Y, Kurosawa S, Ito O, Okamoto T, Takenoyama M, Sumitika H, Nishimura Y, Nomoto K. Generation of tumor-specific cytotoxic T lymphocytes in vivo combined treatment with inactivated tumor cells and recombinant interleukin-2. Cancer Immunol Immunother 1994, 38: 332-338.
27. Yang JC, Perry-Lalley D, Rosenberg SA: An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Responses Mod 1990, 92: 149-159.
28. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with infiltrating lymphocytes. Science 1986, 233: 1318-1321.
29. Klein B, Pals S, Masse R, Lafuma J, Morin M, Binart N, Jasmin JR, Jasmin C: Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride. Int J Cancer 1977, 20: 112-119.
30. Thiéry J-P, Perdereau B, Gongora R, Gongora G, Mazabraud A: Un modèle experimental d'ostéosarcome chez le rat. II L'ostéosarcome greffable du rat. Sem Hôp Paris 1982, 58: 1686-1689.
31. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiéry JP, Gouin F, Rédini F: Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone, 2005, 37: 74-86.
32. Lynch DH, Miller RE: Immunotherapeutic elimination of syngenic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice. Eur J Immunol 1991, 21: 1403-1410.
33. Melief CJ, Kast WM: T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995, 145: 167-177.
34. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G: Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 1992, 34: 241-251.
35. Haanen JB, Baars A, Gomez R, Weber P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ: Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother, in press.
36. Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S: Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract 1998: 194: 679-684.
37. Topalian SL, Muul LM, Rosenberg SA: Growth and immunological characteristics of lymphocytes infiltrating human tumors [abstract]. Surg Forum 1987, 37: 390.
38. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005, 174: 2591-601.
39. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005, 201: 779-791.
40. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005, 65: 2457-2464.
41. + CTLs during functional maturation. J Immunol 2005, 174: 5959-5967.
42. Erman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, Fox JG, Schauer DB: CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 2005, 65: 3998-4004.
43. Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K: Expression of MAGE genes in osteosarcoma. J Orthop Res 1997, 15: 128-132.
44. Ishida H, Komiya S, Inoue Y, Yutani S, Inoue A, Itoh K: Expression of the SART1 tumor-rejection antigen in human osteosarcomas. Int J Oncol 2000, 17: 29-32.
45. Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K, Yamada A: Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res 2001, 19: 346-351.
46. Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T, Sato N: Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 2004, 64: 5442-5448.
47. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001, 7: 3950-3962.
48. Trieb K, Lang S, Kotz R: Heat-shock protein 72 in human osteosarcoma: T-lymphocytes reactivity and cytotoxicity. Pediatr Hematol Oncol 2000, 17: 355-364.